Mechanism of action of anti-HER2 monoclonal antibodies.

The search for new methods of treating cancer, combined with advances in our understanding of carcinogenesis, molecular biology and technology, has resulted in the development of novel biologic agents with proven clinical efficacy. One such agent is trastuzumab (Herceptin), a humanized monoclonal antibody that targets the human epidermal growth factor receptor-2 (HER2). HER2 is a member of a family of receptors that interact with each other and various ligands to stimulate various intracellular signal transduction pathways involved in cell growth control. HER2 is overexpressed in 20%-30% of women with breast cancer and is associated with aggressive tumor characteristics and poor prognosis. Trastuzumab is the first humanized monoclonal antibody to be approved for therapeutic use and the first oncogene-targeted treatment with proven survival benefit in women with HER2-positive metastatic breast cancer. However, its mechanism of action has not been fully characterized and appears to be complex. This paper reviews current knowledge of the mechanism of action of trastuzumab, including HER2 protein downregulation, prevention of HER2-containing heterodimer formation, initiation of G1 arrest and induction of p27, prevention of HER2 cleavage, inhibition of angiogenesis, and induction of immune mechanisms. The significance of these mechanisms for selection of concomitant chemotherapy is also considered.

[1]  M. Hung,et al.  Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A , 1997, Oncogene.

[2]  G. Steger,et al.  Soluble HER‐2/neu neutralizes biologic effects of anti‐HER‐2/neu antibody on breast cancer cells in vitro , 1997, International journal of cancer.

[3]  D. Slamon,et al.  Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. , 1992, Oncogene.

[4]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[5]  G. Clinton,et al.  A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. , 1991, Oncogene.

[6]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[7]  G. Carpenter,et al.  All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.

[8]  H. Rus,et al.  Persistent complement activation on tumor cells in breast cancer. , 1992, The American journal of pathology.

[9]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[10]  Monilola A. Olayioye,et al.  ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner , 1998, Molecular and Cellular Biology.

[11]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[12]  M. Winget,et al.  p 185 HER 2 Monoclonal Antibody Has An ( iproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor , 2022 .

[13]  Y. Ueyama,et al.  In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. , 1996, British Journal of Cancer.

[14]  Yosef Yarden,et al.  A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.

[15]  Lin Yz,et al.  A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. , 1991 .

[16]  P. Toy,et al.  A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. , 1991, Cancer research.

[17]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[18]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Hortobagyi,et al.  Recent developments in breast cancer therapy. , 1999, Seminars in oncology.

[20]  H. Lane,et al.  Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  R. Kumar,et al.  Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells , 1991, Molecular and cellular biology.

[22]  J. Doherty,et al.  NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. , 1998, Cancer research.

[23]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[24]  A. Ullrich,et al.  Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor a in NIH 3T3 cells (gene amplification/receptor transmodulation/tumorigenesis) , 2022 .

[25]  H. Wiley,et al.  The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.

[26]  S. Aaronson,et al.  Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene , 1988, Molecular and cellular biology.

[27]  R. Kerbel,et al.  Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. , 1995, Anti-cancer drugs.

[28]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[29]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[30]  A. Ullrich,et al.  Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. , 1991, Growth regulation.

[31]  能勢 真人.  Antibody-Dependent Cell-Mediated Cytotoxicity〔邦文〕 (リンパ球--活性の1面とその応用 ) , 1975 .

[32]  Z. Fishelson,et al.  Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. , 1999, Immunopharmacology.

[33]  A. Ullrich,et al.  Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Sliwkowski,et al.  Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. , 1994, The Journal of biological chemistry.

[35]  M. Kraus,et al.  Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms. , 1987, The EMBO journal.

[36]  M. Yamakawa,et al.  Protection of thyroid cancer cells by complement‐regulatory factors , 1994, Cancer.

[37]  W. Gullick,et al.  OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.

[38]  P. Munster,et al.  Update on the management of advanced breast cancer. , 1999, Oncology.

[39]  N. Goldstein,et al.  Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.

[40]  S. Ménard,et al.  The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. , 1993, Oncogene.

[41]  M. Goldenberg.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. , 1999, Clinical therapeutics.

[42]  G. Hortobagyi,et al.  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Mendelsohn,et al.  Therapeutic application of anti‐growth factor receptor antibodies , 1998, Current opinion in oncology.

[44]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Baselga,et al.  Advances in Brief Cleavage of the HER 2 Ectodomain Is a Pervanadate-activable Process That Is Inhibited by the Tissue Inhibitor of Metalloproteases-1 in Breast Cancer Cells 1 , 1999 .

[46]  E. Perez.  Current management of metastatic breast cancer. , 1999, Seminars in oncology.

[47]  P. P. Di Fiore,et al.  Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. , 1992, Cancer research.

[48]  Y. Yarden,et al.  The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions , 1997, FEBS letters.

[49]  Y. Yarden,et al.  Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation , 1997, Oncogene.

[50]  D. Slamon,et al.  Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. , 1994, Oncogene.

[51]  T. Fleming,et al.  Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial , 1998 .

[52]  A. Ullrich,et al.  Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.

[53]  A. Ullrich,et al.  Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Robert A. Weinberg,et al.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies , 1985, Cell.

[55]  Jun Yao,et al.  Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. , 1998, Molecular cell.

[56]  J. Weber,et al.  Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases , 1997, Nature.

[57]  D. Slamon,et al.  Radiolabeled antibody targeting of the HER-2/neu oncoprotein. , 1992, Cancer research.

[58]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[59]  V. Chinchilli,et al.  Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[61]  M. Kraus,et al.  Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. , 1989, Genomics.

[62]  G. Yancopoulos,et al.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.

[63]  J. Fraser,et al.  TREATMENT OF EARLY BREAST CANCER , 1978, The Lancet.

[64]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[65]  J. Baselga,et al.  Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. , 1999, Cancer research.

[66]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.